All In Biotech

Investigational drug · Phase 3

Kedrion IVIG 10%

Also called: KIg 10, Immune globulin 10% for administration, QIVIGY

Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Primary Immunodeficiency Disease, Chronic Primary Immune Thrombocytopenia (ITP), Chronic Inflammatory Demyelinating Polyneuropathy.

Phase 3

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

4

4 still active

All registered trials

6

Any phase or sponsor naming "Kedrion IVIG 10%"

First trial start

2021

Mar 31, 2021

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Kedrion IVIG 10%", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Primary Immunodeficiency Disease
  • Chronic Primary Immune Thrombocytopenia (ITP)
  • Chronic Inflammatory Demyelinating Polyneuropathy
  • Stiff Person Syndrome

Approved drugs for the same conditions: Immune thrombocytopenia · Hematology and blood cancers · Cardiovascular and metabolic · Neurology · Rare and genetic disease

Largest trials

Live from ClinicalTrials.gov: studies naming "Kedrion IVIG 10%" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 1 on PubMed

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.